Using secondary data sources for pharmacoepidemiology and outcomes research

Pharmacotherapy

Volumn 29, Issue 2, 2009, Pages 138-153

  Harpe, Spencer E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Administrative databases; Outcomes research; Pharmacoepidemiology; Research methods; Retrospective data; Secondary databases

Indexed keywords

CLINICAL PRACTICE; DATA ANALYSIS; DATA BASE; ELECTRONIC MEDICAL RECORD; ETHICS; GOLD STANDARD; HEALTH CARE; HEALTH CARE QUALITY; HYPOTHESIS; INFORMATION RETRIEVAL; MEDICAL RESEARCH; METHODOLOGY; OBSERVATIONAL STUDY; ORGANIZATIONAL STRUCTURE; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACOEPIDEMIOLOGY; REVIEW; VALIDITY;

DATABASES, FACTUAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOEPIDEMIOLOGY; RESEARCH DESIGN; VOCABULARY, CONTROLLED;

EID: 59949084664     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.2.138     Document Type: Review

References (76)

1. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007;26: 20-36.
2. U. S. Food and Drug Administration. CDER 2005 report to the nation: improving public health thro ugh human drugs. Rockville, MD: Food and Drug Administration, 2005.
3. Perfetto EM, Epstein RS, Moris LS. Assessing patient outcomes of drug therapy: the role of pharmacoepidemiology. In: Hartzema AG, Porta MS, Tilson HH, eds. Pharmacoepidemiology: an introduction, 3rd ed. Cincinnati, OH: Harvey Whitney Books, 1998: 182-212.
4. Schneeweiss S, Avorn J. A review of uses of health care utilizatio n databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58: 323-37.
5. Zhan C, Miller MR. Administrative data based patient safety research: a critical review. Qual Saf Health Care 2003;12(suppl 2): ii58-63.
6. Fairman K, Motheral B. Evaluating medication adherence: which measure is right for your program? J Manag Care Pharm 2000;6: 499 504.
7. Wray NP, Ashton CM, Kuykendall DH, Hollingsworth JC. Using administrative databases to evaluate the quality of medical care: a conceptual framework. Soc Sci Med 1995;40: 1707 15.
8. Applegate RJ, Sacrinty MT, Kutcher MA, et al. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death. Am J Cardiol 2007;99: 333 8.
9. Pakyz A, Powell JP, Harpe SE, Johnson C, Edmond M, Polk RE. Diversity of antimicrobial use and resistance in 42 hospitals in the United States. Pharmacotherapy 2008;28: 906 12.
10. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342: 1907-9.
11. Fautrel B. Pharmacoepidemiology: lessons from real life. Joint Bone Spine 2004;71: 175 7.
12. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342: 1878 86.
13. Liu PY, Anderson G, Crowley JJ. Observational studies and randomized trials [letter]. N EnglJ Med 2000;343: 1195.
14. Smith RP, Meier P. Observational studies and randomized trials [letter]. N Engl J Med 2000;343: 1196.
15. Schneeweiss S. Developments in post-marketing comparative effectiveness research. Clin Pharmacol Ther 2007;82: 143 56.
16. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effect: advantages and disadvantages. Nat Clin Pract Rheumatol 2007;3: 725 32.
17. Gandhi SK, Salmon JW, Kong SX, Zhao SZ. Administrative databases and outcomes assessment: an overview of issues and potential utility J Manag Care Pharm 1999;5: 215-22.
18. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19: 346-66.
19. Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care 2002;40: 675-85.
20. Peabody JW, Luck J, Jain S, Bertenthal D, Glassman P. Assessing the accuracy of administrative data in health information systems. Med Care 2004;42: 1066-72.
21. Iezzoni LI. Coded data from administrative sources. In: Iezzoni LI, ed. Risk adjustment for measuring health care outcomes, 3rd ed. Chicago: Health Administration Press, 2003: 83-138.
22. Jollis JG, Ancukiewicz M, DeLong ER, Pryor DB, Muhlbaier LH, Mark DB. Discordance of databases designed for claims payment versus clinical information systems: implications for outcomes research. Ann Intern Med 1993;119: 844-50.
23. Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K, for the Ischemic Heart Disease Patient Outcomes Research Team. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. J Clin Epidemiol 1994;47: 249-60.
24. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992;82: 243-8.
25. Lau HS, de Boer BA, Beuning KS, Porsius A. Validation of pharmacy records in drug expo sure assessment. J Clin Epidemiol 1997;50: 619-25.
26. Glintborg B, Hillestrom PR, Olsen LH, Dalhoff KP, Poulsen HE. Are patients reliable when self-reporting medication use? Validation of structured drug interviews and home visits by drug analysis and prescription data in acutely hospitalized patients. J Clin Pharmacol 2007;47: 1440-9.
27. Gardner JS, Park BJ, Stergachis A. Automated databases in pharmacoepidemiologic studies. In: Hartzema AG, Tilson HH, Porta MS, eds. Pharmacoepidemiology: an introduction, 3rd ed. Cincinnati, OH: Harvey Whitney Books, 1998: 368-88.
28. Else BA, Armstrong EP, Cox ER. Data sources for pharmaco- economic and health services research. Am J Health Syst Pharm 1997;54: 2601-8.
29. Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med 1997;127: 719-24.
30. Cummings SR, Browner WS, Hulley SB. Conceiving the research question. In: Hulley SB, Cummings SR, Browner WS, et al, eds. Designing clinical research, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2007: 17-26.
31. Mitchell JB, Bubolz T, Paul JE, et al. Using Medicare claims for outcomes research. Med Care 1994;32: JS38-51.
32. Fairman KA. Differentiating effective data mining from fishing, trapping, and cruelty to numbers. J Manag Care Pharm 2007;13: 517-27.
33. Asper F. Using Medicare hospital cost reports cost-to-charge ratios in research (technical note: TN-008). Available from http://www.resdac. umn.edu/Tools/TBs/TN-008-UsingCCRs inResearch-508.pdf. Accessed February 10, 2008.
34. Lave JR, Pashos CL, Anderson GF, et al. Costing medical care: using Medicare administrative data. Med Care 1994;32: JS77-89.
35. Manitoba Centre for Health Policy. Drug classification systems: overview. Available from http://mchp-appserv.cpe. umanitoba.ca/viewConcept.php? conceptID=1123. Accessed February 28, 2008.
36. Polk RE, Fox C, Mahoney A, Letcavage J, MacDougall C. Measurement of adult antibacterial drug use in 130 U.S. hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44: 664-70.
37. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10: 3-12.
38. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154: 854-64.
39. C enters for Medicare and Medicaid Services. Hospital- acquired conditions (present on admission indicator). Available from http://www.cms.hhs. gov/HospitalAcqCond. Accessed February 28, 2008.
40. Newman TB, Browner WS, Hulley SB. Enhancing causal inference in observational studies. In: Hulley SB, Cummings SR, Browner WS, et al, eds. Designing clinical research, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2007: 127-46.
41. . Friis RH, Sellers TA. Epidemiology for public health practice, 2nd ed. Gaithersburg, MD: Aspen Publishers, 1999.
42. Campbell DT, Stanley JC. Experimental and quasi-experimental designs for research. Boston: Houghton Mifflin Co., 1963.
43. Schafermeyer KW, Hurd PD. Research methodology: designing a research study. J Manag Care Pharm 1998;4: 504-14.
44. Etminan M, Samii A. Pharmacoepidemiology I: a review of pharmacoepidemiologic study designs. Pharmacotherapy 2004;24: 964-9.
45. . Etminan M. Pharmacoepidemiology II: the nested case-control study-a novel approach in pharmacoepidemiologic research. Pharmacotherapy 2004;24: 1105-9.
46. Morgenstern H. Ecologic studies. In: Rothman KJ, Greenland S, eds. Modern epidemiology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1998: 459-80.
47. Hill AB. The environment and disease : association or causation? Proc R Soc Med 1965;58: 295-300.
48. Hennekens CH, Buring JE, Mayrent SL. Epidemiology in medicine. Boston: Lippincott Williams & Wilkins, 1987: 45.
49. Rothman KJ. Measuring disease occurrence and causal effects. In: Epidemiology: an introduction. New York: Oxford University Press, 2002: 18-20.
50. Rothman KJ. Biases in study design. In: Epidemiology: an introduction. New York: Oxford University Press, 2002: 94-112.
51. . Strom BL, ed. Sample size considerations for pharmacoepidemiology studies. In: Pharmacoepidemiology, 4 th ed. Chichester, England: John Wiley & Sons, Inc., 2005: 29-36.
52. Green SB. How many subjects does it take to do a regression analysis? Multivariate Behav Res 1991;26: 499-510.
53. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49: 1373-9.
54. Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol 1995;48: 1495-501.
55. van Belle G. Statistical rules of thumb. New York: John Wiley & Sons, Inc., 2002: 29-51.
56. Mills JL. Data torturing. N Engl J Med 1993;329: 1196-9.
57. Smith GD, Ebrahim S. Data dredging, bias, or confounding. BMJ 2002;325: 1437-8.
58. Greenland S, Morgenstern H. Confounding in health research.
59. Annu Rev Public Health 2001;22: 189-212.
60. Altman DG, G oodman SN, S chroter S. Ho w statistical expertise is used in medical research. JAMA 2002;287: 2817-20.
61. Iezzoni LI, ed. Reasons for risk adjustment. In: Risk adjustment for measuring health care outcomes, 3rd ed. Chicago: Health Administration Press, 2003: 1-16.
62. 3M Health Information Systems. All patient refined diagnosis related groups (APR-DRG) version 24.0: methodology overview. Wallingford, CT: 3M Health Information Systems, 2006.
63. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45: 613-19.
64. Clark DO, Von KM, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33: 783-95.
65. Neutel CI. A new, "user-friendly" terminology for confounding by indication in the study of adverse drug reactions. Post Marketing Surveillance 1993;7: 363-9.
66. Blackstone EH. Comparing apples and oranges. J Thorac Cardiovasc Surg 2002;123: 8-15.
67. Shwartz M, Ash AS. Estimating the effect of an intervention from observational data. In: Iezzoni L, ed. Risk adjustment for measuring health care outcomes, 3rd ed. Chicago: Health Administration Press, 2003: 275-95.
68. Rothman KJ. No adjustments are ne eded fo r multiple comparisons. Epidemiology 1990;1: 43-6.
69. National Institutes of Health. Health services research and the HIPAA privacy rule. NIH publication no. 05-5308. Bethesda, MD: National Institutes of Health, 2005.
70. Daley J, Iezzoni LI, Shwartz M. Conceptual and practical issues in developing risk-adjustment methods. In: Iezzoni LI, ed. Risk adjustment for measuring health care outcomes, 3rd ed. Chicago: Health Administration Press, 2003: 179-205.
71. Kohn MA. Data management. In: Hulley SB, Cummings SR, Browner WS, et al, eds. Designing clinical research, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2007: 257-69.
72. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134: 657-62.
73. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147: 573-7.
74. Des Jarlais DC, Lyles C, Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004;94: 361-6.
75. Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies-report of the ISPOR task force on retrospective databases. Value Health 2003;6: 90-7.
76. International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008;17: 200-8.